Skip to main content
. 2022 Dec 13;14(24):6142. doi: 10.3390/cancers14246142

Figure 5.

Figure 5

MRX-2843 monotherapy delays disease progression and prolongs survival in orthotopic T-ALL and ETP-ALL xenograft models. (A–D) NSG mice were injected with a luciferase-expressing T-ALL cell line cells and once-daily oral treatment with MRX-2843 or saline vehicle was initiated after engraftment of disease. (A,C) Disease burden was monitored at intervals by bioluminescence imaging. (B,D) Survival was monitored. (A,B) Mice inoculated with luciferase-expressing Jurkat cells were treated with 75 mg/kg MRX-2843 or saline for 28 days. (A) Mean bioluminescence intensities and SEM are shown (* p < 0.05, **** p < 0.0001, Mann–Whitney-U test, n = 15). (B) Survival was significantly prolonged in mice with Jurkat xenografts treated with MRX-2843 (p < 0.0001, log-rank test, n =10). (C,D) Mice inoculated with luciferase-expressing Loucy cells were treated with 65 mg/kg MRX-2843 or saline until removal from the study. (C) Mean bioluminescence intensities and SEM are shown (** p ≤ 0.01, *** p ≤ 0.001, Mann–Whitney-U test, n = 10). (D) Survival was significantly prolonged in mice with Loucy xenografts treated with MRX-2843 (p = 0.0136, log-rank test, n = 10).